Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on February 28, 2019, covering events occurring on February 22, 2019. The Company is an emerging growth company focused on developing novel therapies targeting neuroinflammation as a cause of Alzheimer's disease.
Key Financial Metrics
This filing does not contain standard financial statements, revenue, profit, cash flow, or debt metrics. The primary financial event reported is the formalization of a grant agreement.
- Grant Award: $1,000,000 total from the Alzheimer's Association.
- Payment Structure: Bi-annual payments contingent on clinical trial milestones.
Material Changes and Agreements
On February 22, 2019, the Company received the Award Letter detailing the conditions for the $1,000,000 grant previously announced on February 13, 2019. The funds are designated to advance XPro1595, a therapy for Alzheimer's disease. Payments are structured as follows:
- $600,000: Due June 15, 2019, upon regulatory approval to open the clinical trial and enrollment of the first patient.
- $250,000: Due between June 15 and December 15, 2019, contingent on all patients in the first cohort reaching the one-month milestone and enrollment of the first patient in the second cohort.
- $150,000: Due between December 15, 2019, and June 15, 2020, contingent on all patients in the second cohort reaching the one-month milestone and enrollment of the first patient in the third cohort.
Outlook, Risks, and Other Information
The Company announced that its founders will present at the World Immunotherapy Congress USA during the Festival of Biologics San Diego from March 3 to March 5, 2019. The filing explicitly states that the information regarding this presentation is not deemed "filed" for purposes of Section 18 of the Exchange Act and does not constitute material investor information not otherwise publicly available. The receipt of grant funds is subject to the successful achievement of specific clinical milestones.
Investor Verification Checklist
- Verify the status of regulatory approval for the Phase 1 clinical trial required to trigger the initial $600,000 payment.
- Confirm the enrollment timeline for the first patient in the XPro1595 trial.
- Review the full text of the Award Letter (Exhibit 1.1) for additional conditions or clawback provisions not summarized in the 8-K.
- Monitor the Company's cash runway given the milestone-dependent nature of the grant funding.